Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.50 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16805354 | 1.00 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL16452370 | 0.91 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL15497392 | 0.91 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL13018205 | 0.91 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL18852608 | 0.91 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL15276409 | 0.91 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL14929229 | 0.90 | P2RY14 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL16805325 | 0.90 | P2RY14 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL25718206 | 0.89 | LMNA (0.53) | SLC28A1SLC28A2SLC29A1SLC28A3TDP1 | |
| SCHEMBL16808980 | 0.88 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20160354493-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-9428535-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNA THERAPEUTICS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | SLC28A1 231/4885SLC28A2 204/4885SLC29A1 178/4885 |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | SLC28A1 231/4885SLC28A2 204/4885SLC29A1 178/4885 |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | SLC28A1 80/4885SLC28A2 66/4885SLC29A1 41/4885 |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | SLC28A1 231/4885SLC28A2 204/4885SLC29A1 178/4885 |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | SLC28A1 317/4885SLC28A2 259/4885SLC29A1 239/4885 |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | SLC28A1 231/4885SLC28A2 204/4885SLC29A1 178/4885 |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | SLC28A1 231/4885SLC28A2 204/4885SLC29A1 178/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | SLC28A1 317/4885SLC28A2 259/4885SLC29A1 239/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | SLC28A1 317/4885SLC28A2 259/4885SLC29A1 239/4885 |
| US-20160354493-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | SLC28A1 231/4885SLC28A2 204/4885SLC29A1 178/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | SLC28A1 231/4885SLC28A2 204/4885SLC29A1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.